Last reviewed · How we verify
FOLFOX 2d
FOLFOX 2d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin administered on a modified 2-day schedule to inhibit DNA synthesis and induce apoptosis in cancer cells.
FOLFOX 2d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin administered on a modified 2-day schedule to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Colorectal cancer (likely primary indication based on FOLFOX standard use).
At a glance
| Generic name | FOLFOX 2d |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Combination chemotherapy regimen |
| Target | Thymidylate synthase (5-FU); DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX is a combination chemotherapy regimen where 5-fluorouracil (5-FU) inhibits thymidylate synthase to disrupt DNA synthesis, leucovorin enhances 5-FU activity by stabilizing its binding to the enzyme, and oxaliplatin is a platinum agent that forms DNA cross-links. The '2d' designation indicates a modified 2-day infusion schedule variant of the standard FOLFOX protocol, designed to optimize dosing and tolerability.
Approved indications
- Colorectal cancer (likely primary indication based on FOLFOX standard use)
Common side effects
- Neutropenia
- Neuropathy (peripheral)
- Nausea and vomiting
- Diarrhea
- Anemia
- Mucositis
Key clinical trials
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer (PHASE2)
- Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin (PHASE1)
- FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer (PHASE2)
- HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study (PHASE3)
- The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts (PHASE3)
- The Clinical Study of Adjuvant Chemotherapy on Intestinal and Urethral Flora in Patients With Gastric and Colon Cancer (NA)
- Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFOX 2d CI brief — competitive landscape report
- FOLFOX 2d updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI